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Dosage adjustment of anti-epileptic drugs by therapeutic drug monitoring (TDM) is very useful, 
especially for the first-generation anti-epileptic drugs (AEDs). Microsampling -the collection of small 
volumes of blood- is increasingly considered a valuable alternative to conventional venous sampling 
for TDM. Volumetric absorptive microsampling (VAMS) allows accurate and precise collection of a 
fixed volume of blood, eliminating the volumetric blood hematocrit bias coupled to conventional 
dried blood spot collection. The aim of this study was to develop and validate an LC-MS/MS method 
for the determination and quantification of four anti-epileptic drugs (carbamazepine, valproic acid, 
phenobarbital and phenytoin) and one active metabolite (carbamazepine-10,11-epoxide) in samples 
collected by VAMS. The method was fully validated based on international guidelines. Precision  
(%RSD) was below 10%, while, with a single exception, accuracy (%bias) met the acceptance criteria. 
Neither carry-over nor unacceptable interferences were observed, the method being able to 
distinguish between the isomers oxcarbazepine and carbamazepine-10,11-epoxide. All compounds 
were stable in VAMS samples for at least 1 month when stored at room temperature, 4 °C and -20 °C 
and for at least 1 week when stored at 60 °C. Internal standard-corrected matrix effects were below 
10%, with %RSDs below 4 %. High (>85%) recovery values were obtained and the effect of the 
hematocrit on the recovery was overall limited. Successful application on external quality control 
materials and on left-over patient samples demonstrated the validity and applicability of the 
developed procedure. 
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Introduction 
Whether a patient with epilepsy is free from seizures and is able to live a normal life depends on the 
correct administration of appropriate anti-epileptic drugs (AEDs). AEDs can be divided into three 
subclasses: the ‘classical’ or ‘first-generation’ AEDs, the ‘second-generation’ AEDs and the ‘third-
generation’ AEDs [1]. Carbamazepine, phenobarbital, phenytoin and valproic acid were introduced 
prior to 1990 and belong to the first-generation AEDs [1]. Oxcarbazepine, vigabatrin and topiramate, 
amongst others, are examples of the second-generation AEDs, while lacosamide, retigabine and 
eslicarbazepine are categorized as third-generation AEDs [1]. Significant interindividual variability in 
pharmacokinetics (absorption, distribution, metabolism and excretion) is one of the commonly 
known properties of first-generation AEDs, making optimization and individualization of the therapy 
quite challenging [2]. 
Therapeutic drug monitoring (TDM) serves as an excellent tool in the optimization and 
individualization of drug therapy. The generally narrow therapeutic indices of first-generation AEDs, 
causing toxicity to be a common issue, have led to the fact that TDM has become an established 
application, in general as well as in special populations (e.g. children, elderly and pregnant women 
with epilepsy).  
TDM is most often performed on venous blood samples (whole blood, plasma or serum). However, 
given the invasive nature of the associated sampling and the relatively large amounts of blood that 
are typically taken, this sampling procedure becomes increasingly less attractive in clinical practice. In 
addition, as sampling requires a phlebotomist, patients are obliged to visit a hospital or doctor’s 
office for a venous blood draw. Therefore, there is a growing interest in the use of non- and 
minimally invasive alternative sampling strategies for TDM [3, 4]. 
One of the most commonly used alternative sampling strategies is dried blood spot (DBS) sampling. 
Generally, DBS are prepared by depositing a drop of capillary blood, obtained by a finger or heel 
prick, on a dedicated filter paper. Over the past years, several methods were published using DBS for 
the determination of both first- and second-generation AEDs [5-12]. DBS sampling -for TDM and in 
general- has several advantages over conventional venous blood sampling. As DBS are mostly 
obtained by a finger prick, the patients themselves can perform sampling at home. Furthermore, as 
the resulting dried matrix is considered non-contagious, sending DBS via regular mail to the clinical 
laboratory is allowed [13]. This way, laboratory results may already be available before a patient 
visits the doctor’s office for follow-up. Besides, sending the samples by airmail can also be 
advantageous in countries where patients have to cover a long distance to clinical practices. The 
small sample volume (typically 3 - 12 µL) associated with DBS sampling is another benefit, particularly 
for special populations, such as neonates and anemic patients. In addition, the sampling procedure is 
accompanied by increased analyte stability and by fewer difficulties with respect to sample handling, 
storage and transport [13]. Given all these benefits, DBS sampling can serve as an excellent 
alternative to conventional venous sampling for TDM of AEDs. 
On the other hand, DBS sampling is also struggling with some challenges, with the hematocrit (Hct) 
issue undoubtedly being the most widely discussed one. In essence, because of Hct-dependent 
spreading of blood on filter paper (blood with higher Hct spreading less), partial punch analysis of a 
DBS (which is the approach mostly used) will most often yield a bias for DBS generated from blood 
with divergent (either low or high) Hct. However, several strategies have been developed that allow 
to cope with the issues coupled to a varying Hct [14-22]. One of the proposed approaches is the use 
of volumetric absorptive microsampling (VAMS) devices [23, 24]. The latter are handheld devices 
consisting of a hydrophilic polymer tip connected to a plastic handler, which wicks up a fixed volume 
(approximately 10 or 20 μL) when contacting a blood surface [24]. Using authentic samples with a 
wide Hct range (0.21-0.50), our lab readily demonstrated that VAMS effectively results in absorption 
of a fixed volume of blood, irrespective of the hematocrit [23]. Furthermore, VAMS still maintains the 
benefits associated with DBS sampling and was reported to be preferred over DBS sampling by 
patients in a home sampling context [25]. The associated cost, as well as current incompatibility with 
on-line analysis systems, as developed for DBS analysis, may be considered disadvantages. In 
addition, we -as well as others- found that, while VAMS effectively allows volumetric sampling 
(thereby not suffering from a Hct effect as observed in DBS), recovery may be impacted by Hct [23, 
26]. 
The aim of this study was to develop, validate and apply an ultra-performance liquid chromatography 
- tandem mass spectrometry (UPLC®-MS/MS) method for the determination and quantification of 
four AEDs and one active metabolite, including carbamazepine (CBZ), valproic acid (VPA), phenytoin 
(PHT), phenobarbital (PB) and carbamazepine-10,11-epoxide (CBZ-E), making use of VAMS devices. 
We thereby paid particular attention to the recovery issue associated with analysis of VAMS devices. 
CBZ, VPA, PHT and PB were chosen since they belong to the first-generation AEDs class, for which the 
strongest evidence for TDM exists. Furthermore, this type of AEDs is still frequently used for seizure 
control in developing countries, where microsampling may offer the largest benefits [27, 28]. CBZ-E, 
an active metabolite of CBZ, was also incorporated in the multi-analyte method as it is equipotent to 
CBZ and hence contributes significantly to its therapeutic (or toxic) effects [29]. Furthermore, since in 
MS/MS the multiple reaction monitoring (MRM) transitions characteristic for CBZ-E are the same as 
those for its isomer oxcarbazepine (OXC), OXC was also incorporated to assess the capability of the 
method to distinguish between CBZ-E and OXC, rather than to quantitatively determine OXC.
 
Materials and methods 
Chemicals and stock solutions 
LC-MS grade acetonitrile was obtained from Biosolve (Valkenswaard, The Netherlands). A Synergy® 
Water Purification System (Merck Millipore, Overijse, Belgium) provided ultrapure water. Valproic 
acid, valproic acid-d6, phenytoin, phenytoin-d5, carbamazepine, carbamazepine-d10, oxcarbazepine, 
carbamazepine-10,11-epoxide and ammonium acetate were purchased from Sigma Aldrich (Diegem, 
Belgium). Phenobarbital and phenobarbital-d5 were derived from LGC standards (Molsheim Cedex, 
France). Oxcarbazepine-d10 was obtained from Santa Cruz Biotechnology, Inc. (Heidelberg, 
Germany) and carbamazepine-10,11-epoxide-d10 from J.H. Ritmeester B.V. (Nieuwegein, The 
Netherlands).  
Taking into account the upper and lower limit of the therapeutic range of each compound, 
methanolic stock solutions were prepared at 40, 50, 10, 10 and 5 mg/mL for VPA, PB, PHT, CBZ and 
CBZ-E, respectively. For OXC, a 1.67 mg/ml stock solution was prepared in acetonitrile. For the 
preparation of the calibrators and quality control samples (QCs), independently prepared stock 
solutions were used. For the internal standards (IS) of PHT, CBZ and PB, methanolic stock solutions of 
0.1 mg/mL were purchased, while for VPA the concentration of the IS stock solution was 1 mg/mL. IS 
stock solutions for CBZ-E and OXC (1 mg/mL) were prepared in methanol and acetonitrile, 
respectively. Working solutions of the standards and the IS were prepared the day of analysis by 
diluting the stock solutions with water. All solutions -except for the stock solution of CBZ-E (4 °C)- 
were stored at -20 °C in 1.5 mL amber glass vials derived from VWR® (Leuven, Belgium). 
Sample collection 
Venous whole blood from an AED abstinent healthy, female volunteer was collected in EDTA tubes 
(BD Vacutainer® with BD Hemogard® closure 10 mL) for method development and validation 
purposes. VAMS devices (Mitra™) were obtained from Neoteryx (Torrance, CA, USA). Samples were 
prepared by dipping the tip into spiked whole blood in 2 mL eppendorf tubes. Overfilling of the 
devices was prevented by not completely immersing the tip into the blood. After completely filling 
the tips, the devices were dried in the accompanying clamshells for 2 hours at ambient temperature. 
Once dried, the VAMS devices were stored at room temperature in zip-closure plastic bags, 
containing two 5 g packages of desiccant (Minipax® absorbent packets, Sigma Aldrich) until UPLC®-
MS/MS analysis. 
Sample preparation 
Sample preparation was performed by separating the VAMS tips from the plastic handlers and 
transferring these into 2 mL eppendorf cups. Extraction was carried out using a Thermo-shaker TS-
100C (BioSan, Riga, Latvia). In order to optimize the extraction conditions, different combinations of 
water and acetonitrile were evaluated, as well as different extraction solvent volumes (varying from 
70 to 140 μL), extraction times and temperatures. For each of the tested conditions, spiked VAMS 
devices were analyzed in triplicate and the final sample preparation method was selected based on a 
comparison of the peak areas obtained for each condition. 
Preparation of calibrators and QCs 
Calibrators were made at eight concentration levels in blank whole blood. For each compound -
except for VPA- the lower limit of the therapeutic range in plasma divided by two was set as the 
lower limit of quantification (LLOQ) and the upper limit of the therapeutic range times four as the 
upper limit of quantification (ULOQ). The resulting calibrator concentrations were 1, 1.5, 2, 33.6, 
65.2, 96.8, 128.4 and 160 µg/mL for PB; 4, 6, 8, 22.4, 36.8, 51.2, 65.6 and 80 µg/mL for PHT; 2, 3, 4, 
12.8, 21.6, 30.4, 39.2 and 48 µg/mL for CBZ and 0.25, 0.375, 0.5, 5.2, 9.9, 14.6, 19.3 and 24 µg/mL for 
CBZ-E. For VPA, detector oversaturation occurred with concentrations at four times the upper limit of 
the therapeutic range, therefore the upper limit of the therapeutic range times 1.5 was used as 
ULOQ, yielding calibrators at 25, 37.5, 50, 70, 90, 110, 130 and 150 µg/mL. Also when taking into 
account blood/plasma ratios (see further), these calibration lines cover the anticipated therapeutic 
ranges in blood. QC solutions (LLOQ, Low, Mid, High, respectively) were prepared in blank whole 
blood at 25, 55, 100, 112.5 µg/mL for VPA; 1, 3, 40, 120 µg/mL for PB; 4, 8, 20, 60 µg/mL for PHT; 2, 
5, 12, 36 µg/mL for CBZ; 0.25 and 1.50, 6, 18 µg/mL for CBZ-E. Non-matrix solvents were never added 
in a proportion higher than 5 % of the total sample volume. 
UPLC® -MS/MS method 
A Waters Acquity UPLC® system (Waters, Milford, MA, USA) coupled to a SCIEX API™ 4000 mass 
spectrometer (SCIEX, Framingham, MA, USA) was used for all analyses. The hardware system was 
controlled by SCIEX Analyst® 1.6.2 and by the Waters Acquity console software. 
The deviating characteristics of the 6 compounds, combined with the inability of the utilized 
configuration to switch between positive and negative ionization modes, necessitated development 
of two different UPLC®-MS/MS methods, one operating in negative ionization mode (method I, 
monitoring VPA, PB and PHT) and one in positive ionization mode (method II, monitoring CBZ, CBZ-E 
and OXC). 
For both methods, a Chromolith® reversed phase (RP)-18 endcapped 100x4.60 mm column (Merck 
Millipore, Overijse, Belgium), equipped with the corresponding guard column, was chosen as it gave 
the best results in terms of compound separation. The column oven was set at 45 °C. A mobile phase 
consisting of 5 mM ammonium acetate (A) and 5 mM ammonium acetate in acetonitrile/water (95/5, 
v/v) (B) at a flow rate of 1.4 mL/min turned out to be the best option. The total run time was 10 min, 
including a 4-min run for method I and a 6-min run for method II. The mobile phase gradient program 
for method I started with 20 % solvent B, linearly increased to 60 % in 1 min, followed by an increase 
to 98 % in 0.5 min, maintained for 1 min and finally, reversal to starting conditions. For method II, the 
gradient started with 10 % solvent B, followed by a linear increase to 27 % in 0.22 min, isocratic 
conditions for 0.28 min, an increase to 31 % in 1.72 min, followed by a rise to 98 % in 0.88 min, kept 
for 0.8 min and finally, returning to starting conditions. 
The API™ 4000 mass spectrometer was equipped with an ESI source (TurboIonSpray®) and used an 
optimized multiple reaction monitoring (MRM) algorithm for detection. The source temperature was 
set at 600 °C, the ion spray voltage at -3000 V for method I and at 2000 V for method II. Nitrogen was 
used as nebulizer (gas 1), heater (gas 2), curtain (CUR) and collision-activated dissociation (CAD) gas, 
with following gas pressure settings: 90 psi for gas 1, 10 psi for gas 2, 20 and 40 psi (respectively for 
method I and II) for CUR and the CAD vacuum was set at 12 for both methods (arbitrary settings). 
For PB, PHT, CBZ, CBZ-E and OXC, two characteristic precursor-to-product ion transitions were 
monitored, while for the corresponding internal standards one transition was analyzed. Since no 
stable ion fragments are created for VPA, a pseudo mass transition (143.1/143.1) was monitored. 
Supplementary table 1 shows all MRM transitions, together with the compound-specific MS 
parameters (optimized following infusion). 
Method validation 
Method validation was based on U.S. Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) guidelines for bioanalytical method validation [30, 31] and covered accuracy, 
precision, carry-over, selectivity, homoscedasticity, calibration model, stability, matrix effect, 
recovery and Hct effect. Control blanks (i.e. VAMS samples prepared with blank blood and analyzed 
without IS in the extraction solvent) and zero samples (i.e. VAMS samples prepared with blank blood 
and analyzed with the regular extraction solvent) were assessed throughout each sequence. 
Accuracy (%bias) and precision (% relative standard deviation, %RSD) were assessed by analyzing QCs 
(LLOQ, Low, Mid and High) in duplicate on 4 different days. The intra- and inter-batch precision were 
determined using ANOVA, whereas the accuracy was calculated by dividing the difference between 
the obtained concentration and the nominal value by the nominal value, and multiplying by 100 [32]. 
The %bias and %RSD should be within ±15 % for the QC samples, except for the LLOQ, where they 
should be within ±20 % [31]. 
Carry-over was examined by analysis of 2 blank samples after measurement of the highest calibrator 
(ULOQ), on 4 different days (n=8). Carry-over for the analytes should not exceed 20 % of the peak 
area found for the LLOQ and 5 % for the IS [31]. For selectivity, identical criteria were applied. 
Selectivity was assessed by analyzing blank VAMS samples prepared with whole blood from 6 
different individuals. 
The LLOQ was defined for each of the AEDs as the lower limit of the therapeutic range divided by 
two. These concentrations gave a signal of at least 10 times the signal of a blank sample. A 
chromatogram of each compound at the LLOQ level is provided in supplementary data. 
Homoscedasticity and the calibration model were evaluated by generating eight eight-point 
calibration curves. Homoscedasticity was tested by performing an F-test (α=1 %) at the lowest and 
highest calibrator. Furthermore, for the calibration model, both weighted (1/x, 1/x2, 1/√x, 1/y, 1/y2 
and 1/√y) and unweighted linear and quadratic regression were performed in order to find the best 
fitting model. The resulting models were compared by calculating the sum% relative error (%RE) and 
by plotting the %RE against nominal concentrations. Before accepting a selected model, a back-
calculation was performed in which the mean concentrations of the calibrators should be within ±15 
% of the nominal value or within ±20 % for the LLOQ [31]. 
Short- and long-term stability were assessed by analyzing Low and High QCs (n=3) in duplicate after 
storage for 4, 7 and 30 days at different temperatures (-20 °C, 4 °C, room temperature and 60 °C) in a 
zip-closure plastic bag containing two 5 g packages of desiccant. As reference, QCs, prepared at the 
same day of the QCs used for stability testing, were analyzed at time point zero. Autosampler 
stability (4 °C) was evaluated by storing the extracts of Low and High QCs for 24h in the autosampler 
before reinjection. At each day of analysis, an eight-point calibration curve was freshly prepared in 
order to calculate the concentration of the stored VAMS/extracts. Here again, the mean 
concentration of the QCs, at a particular time point should not deviate more than ±15 % from the 
nominal concentration [31]. 
Matrix effects were investigated by comparing the peak areas obtained at two concentration levels 
(Low or High QC), spiked to blank blood extract (from six different individuals, with a hematocrit 
ranging from 0.335 to 0.495) (A), with those obtained using a neat aqueous mixture containing the 
analytes and their IS at corresponding concentrations (B). The ratios of peak areas of (A) to those of 
(B), multiplied by 100 represent the IS-corrected matrix effect. Overall, the %RSD of the IS-corrected 
matrix effect should not exceed ±15 % [31]. 
The impact of the Hct on the recovery was evaluated for Low and High QC’s (n=6) at four different 
Hct levels (target values at 0.21, 0.42, 0.52 and 0.62), prepared by centrifuging an aliquot of blood 
with a hematocrit of 0.40 in 2 mL eppendorf tubes in an Eppendorf 5804R centrifuge (Hamburg, 
Germany) for 5 min at 1000g and by removing or adding plasma. Here, two sets of VAMS samples 
were compared to one another, i.e. VAMS samples prepared by pipetting 10 µL of spiked blood (C) 
and VAMS samples prepared by pipetting 10 µL of blank blood and to which the analytes were only 
spiked post-extraction (D). The absolute recovery values (%) were calculated by multiplying the ratios 
of peak areas of (C) to those of (D) by 100. To further evaluate the impact of the Hct, VAMS samples 
(n=6) were also prepared by dipping them into spiked blood at four different Hct levels (target values 
at 0.21, 0.42, 0.52 and 0.62). The latter better reflects the reality when compared to pipetting of a 
fixed volume onto the VAMS devices. 
Where relevant, statistical analyses were performed using the Minitab® software. 
Application 
In order to objectively indicate the validity of the obtained results, 3 sets of external serum QC 
materials were used to generate QCs in blood and VAMS samples derived thereof. The QC materials 
were the ClinCal®-calibrator (Recipe®, Munich, Germany) containing PB 37.5 µg/mL, PHT 18.3 µg/mL, 
VPA 90.7 µg/mL, CBZ 11.2 µg/mL and CBZ-E 5.60 µg/mL in serum and the Liquichek™ Therapeutic 
Drug Monitoring Control (TDM) Levels 2 and 3 (Bio-Rad, California, USA) containing PB 34.7 µg/mL, 
PHT 15.2 µg/mL, VPA 85.6 µg/mL and CBZ 9.11 µg/mL in serum (level 2) and PB 65.0 µg/mL, PHT 31.8 
µg/mL, VPA 134 µg/mL and CBZ 13.1 µg/mL in serum (level 3). In order to be comparable with a 
calibration curve prepared in whole blood, the external QC materials were diluted 1 on 4 with whole 
blood, by replacing 250 µL of plasma (obtained by centrifugation of 1 mL of whole blood) by 250 µL 
of the external QC materials. Due to this dilution, some concentration were no longer within the 
calibration range and, hence, could not be quantified. The resulting concentrations in blood of the 
used external QC materials were 33.5 µg/mL for VPA (Liquichek™ Level 3); 8.68, 9.38 and 16.3 µg/mL 
for PB (Liquichek™ Level 2, ClinCal® and Liquichek™ Level 3, respectively); 4.58 and 7.95 µg/mL for 
PHT (ClinCal® and Liquichek™ Level 3, respectively); 2.28, 2.80 and 3.28 µg/mL for CBZ (Liquichek™ 
Level 2, ClinCal® and Liquichek™ Level 3, respectively) and 1.40 µg/mL for CBZ-E (ClinCal®). 
Furthermore, as a proof of concept, we analyzed 30 samples, collected at Ghent University Hospital 
from patients who visited the Hospital for evaluation of a variety of parameters, including follow-up 
of their AED treatment. VAMS samples were prepared by wicking up EDTA-anticoagulated blood 
from routine leftover whole blood samples that had been stored at room temperature for maximum 
72 h. Approval for this study was provided by the Ethics Committee of Ghent University Hospital 
(EC2017/0572).
 
Results and discussion 
Sample preparation 
As the IS are in the extraction solvent, these do not compensate for recovery issues [33]. Therefore, 
optimization of sample extraction was comprehensively implemented. During this optimization, 
extraction at 22 °C and at 60 °C was compared, using freshly prepared VAMS samples, VAMS samples 
stored for 3 days at room temperature and VAMS samples stored for 3 days at 60 °C. The VAMS were 
prepared by using spiked whole blood (Low QC level) with a Hct of 0.41. Also a comparison was made 
with VAMS samples prepared from blood at a Hct of 0.62, stored for 3 days at 60 °C and extracted at 
22 °C and at 60 °C. 
As Figure 1 depicts, extraction of the VAMS at elevated temperature (60 °C) provided overall the best 
results in terms of absolute recovery. Based on these findings, hundred μL of an acetonitrile/water 
(80/20, v/v) mixture, containing 5 mM ammonium acetate and the deuterated internal standards 
(0.5 μg/mL) was eventually used to extract VAMS devices by shaking for 10 min at 1000 rpm and 60 
°C. Following centrifugation at ambient temperature for 10 min at 10 000 g, 70 μL of supernatant was 
diluted 1 on 1 with water containing 5 mM ammonium acetate. This mixture was transferred to an 
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Figure 1 
Optimization of sample extraction: comparison of extraction at 22 °C and at 60 °C, using VAMS samples, spiked at Low QC, 
which were freshly prepared or stored for 3 days at RT (Hct 0.41) or were stored for 3 days at 60 °C (Hct 0.41 and Hct 0.62). 
Shown are the mean and standard deviation (n=6). Asterisks denote statistical differences (p<0.05, 2-sided t-test) between 
extraction at 22 °C and 60 °C. 
Method validation 
With the exception of VPA (18.2 %bias at Low QC), the acceptance criteria for accuracy (%bias below 
20% at LLOQ and below 15% at the other QC levels) was met. With an intra- and inter-batch precision 
(%RSD) below 10%, acceptance criteria were met for all compounds (Table 1). 
Table 1 
Intra- and inter-batch precision (%RSD) and accuracy (%bias) for QCs of VPA, PB, PHT, CBZ and CBZ-E at four concentration 
levels in VAMS samples (n=4 x 2). 
QC
Intra-batch precision (%RSD) (n=4x2)
VPA PB PHT CBZ CBZ-E
LLOQ 7.47 9.76 8.60 8.76 7.67
Low 3.83 7.25 6.60 7.48 6.54
Mid 5.61 4.49 7.86 5.99 5.32
High 8.29 3.87 4.11 8.96 5.08
Inter-batch precision (%RSD) (n=4x2)
VPA PB PHT CBZ CBZ-E
LLOQ 7.47 9.76 8.60 8.76 7.67
Low 8.15 7.83 6.60 7.48 6.63
Mid 5.61 4.49 7.86 7.34 5.32
High 8.29 6.16 7.68 8.96 5.08
Accuracy (%Bias) (n=4x2)
VPA PB PHT CBZ CBZ-E
LLOQ -15.3 -1.42 4.22 9.85 4.02
Low 18.2 -1.48 0.87 0.72 14.0
Mid -1.14 -2.70 3.71 8.15 8.22
High -1.32 1.51 4.84 2.01 4.97
 
No carry-over was detected when injecting blank samples after the highest calibrator and, regarding 
selectivity, no unacceptable interferences were observed in VAMS samples prepared from blank 
blood originating from 6 different donors. Importantly, a considerable advantage is the possibility to 
distinguish between CBZ-E and OXC (retention times of 2.64 and 2.88 min, respectively), although 
they have the same MRM transitions (see chromatograms at LLOQ levels in supplementary data). 
Therefore, the presence of OXC in a patient sample will not interfere with the calculated CBZ-E 
concentration. 
Calibration data for all compounds were found to be heteroscedastic. Only for PHT, weighted 
regression did not improve the %RE, therefore the simplest model, i.e. unweighted linear regression, 
was chosen. The selected weighting factors for PB, CBZ and CBZ-E were 1/x, 1/x² and 1/x, 
respectively. Based on %RE values, weighted quadratic regression was chosen for VPA, with a 
weighting factor 1/x. Using these selected models, mean back-calculated concentrations did not 
differ more than 7 % for all calibrators, which is in line with the acceptance criteria [31]. 
As displayed in Table 2, all compounds were stable in VAMS samples for at least 1 month when 
stored at room temperature, 4 °C and -20 °C and for at least 1 week when stored at 60 °C. The latter 
is important when envisaging e.g. sampling in and/or shipping from countries with high ambient 
temperatures. Re-analysis of Low and High QCs after storage for 24h in the cooled autosampler (4 °C) 
revealed autosampler stability for all compounds and their corresponding IS. 
Table 2 
Stability data for VPA, PB, PHT, CBZ and CBZ-E in VAMS samples at Low and High QC (n=3), measured in duplicate. Data are 
presented as the percentage difference between the concentration measured at the specific time points and the nominal 
values. 
Temp Stability for 4 days (%difference) (n=3)
VPA PB PHT CBZ CBZ-E
Low QC High QC Low QC High QC Low QC High QC Low QC High QC Low QC High QC
RT -6.04 -9.32 -5.34 -6.15 -8.43 4.16 -9.22 -5.51 7.45 -4.31
4 °C 2.06 2.03 5.16 -0.40 -0.75 12.4 -0.31 4.69 15.9 5.29
-20 °C 12.1 0.25 8.29 -6.23 1.54 9.95 0.38 -3.61 17.5 0.02
60 °C 2.30 -2.33 0.03 -7.84 -4.85 3.03 -12.1 -5.12 2.87 -9.24
Stability for 1 week (%difference) (n=3)
RT 11.5 0.74 -6.01 -10.5 -8.33 9.60 -13.7 -8.83 5.94 -0.10
4 °C 11.8 -7.97 -7.22 -13.6 -8.37 3.75 -13.9 -13.5 6.89 -5.42
-20 °C 11.8 -4.42 -3.09 -11.8 -6.12 5.20 -13.4 -14.9 4.98 -0.76
60 °C 6.30 -7.97 0.56 -12.97 -10.3 2.31 -10.9 -12.3 -5.94 -15.3
Stability for 1 month (%difference) (n=3)
RT 17.6 10.4 5.07 0.27 11.9 9.18 -4.58 3.15 4.01 -4.12
4 °C 15.1 18.0 7.00 5.88 11.8 7.75 -3.64 -0.91 11.4 -1.66
-20 °C 15.5 17.6 13.2 7.36 9.46 7.38 -1.75 1.67 5.11 -0.22
60 °C 16.3 28.1 15.5 6.77 11.0 13.3 -10.8 -0.85 -23.6 -26.1
 
Based on the results provided in Table 3, the values for the non-IS-corrected analyte matrix effects 
indicated relevant (> 15 %) suppression of ionization for PHT, while relevant (>15 %) enhancement of 
ionization was observed for CBZ and CBZ-E. However, the IS-corrected matrix effects were all within 
90-103 %, indicating that the IS compensate for the differences in ionization. Importantly, the %RSD 
of the IS-corrected matrix effects was below 4 % in all instances, meeting the pre-set acceptance 
criterium of 15 % [31]. 
Table 3 
Analyte matrix effect and IS-corrected matrix effect (n=6) for VPA, PB, PHT, CBZ and CBZ-E. 
Analyte matrix effect (n=6)





















Mean of 6 donors (%) 95.0 95.0 112 103 81.2 79.5 127 131 134 138
%RSD 3.64 3.36 5.11 4.82 2.29 2.12 10.7 8.08 12.4 11.6
IS-corrected matrix effect (n=6)





















Mean of 6 donors (%) 103 102 98.3 95.7 98.6 95.6 93.1 90.4 95.4 99.0
%RSD 1.21 1.83 1.92 1.58 3.91 3.01 1.67 0.93 1.70 3.97
 
The possibility of a Hct-dependent recovery, when using VAMS, is a well-known issue [23, 26]. 
Furthermore, as demonstrated by Abu-Rabie et al., a high recovery is important to minimize the risk 
of being confronted with a significant Hct-based recovery bias [33]. In a first stage, recovery was 
evaluated by pipetting a fixed volume (10 µL) of blood onto the VAMS. High recoveries were 
obtained for all compounds, at 85.2 ± 6.1 % for VPA, 93.7 ± 4.6 % for PB, 85.4 ± 5.9 % for PHT, 86.4 ± 
5.9 % for CBZ and 91.4 ± 4.6 % for CBZ-E, these values corresponding to the averages calculated from 
all values obtained at all Hct levels and at Low and High QC level. Furthermore, as shown in Figure 2, 
overall, apart from VPA (High QC) at high Hct (0.62), the Hct did not significantly affect the recovery. 
In addition, when normalizing the 0.42 Hct level to 100 % (see figure 2 in supplementary data), all 
recoveries -except for VPA- were within 15 % of the 0.42 Hct reference sample. For VPA, the low QC 
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Figure 2 
IS-compensated recovery (%) at Low and High QC level (n=6) for VPA, PB, PHT, CBZ and CBZ-E measured in VAMS samples, 
prepared by pipetting 10 µl blood at 4 different Hct levels (target values at 0.21, 0.42, 0.52 and 0.62). Shown are the mean 
and standard deviation. Asterisk denotes statistical difference (p<0.05, one-way ANOVA test) from the 0.42 Hct reference 
sample. 
To further evaluate the impact of the Hct, VAMS samples were also prepared by dipping them into 
spiked blood (Low and High QC) at four different Hct levels (target values at 0.21, 0.42, 0.52 and 
0.62). As Figure 3 depicts, all were within 16 % of the 0.42 Hct sample, except for PB at 0.62 Hct (Low 
QC) and 0.52 Hct (High QC). However, one-way ANOVA analyses revealed that the observed 
differences for PB were not statistically significant (p=0.303 and 0.082, respectively). 
Taking these findings into account, it can be concluded that if there is an effect of the Hct on the 
recovery, it is overall limited. As in some cases there is a trend towards somewhat lower recoveries in 
samples with very high Hct values, it is recommended to be cautious when analyzing patient samples 
with a Hct above 0.60. Given the overall limited influence at low to normal Hct values and since we 
aim at applying the developed method on patient samples originating from children living in 
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Figure 3 
Influence of the hematocrit on the recovery of VPA, PB, PHT, CBZ and CBZ-E, with the 0.42 Hct sample being normalized to 
100 %. Here, VAMS samples were prepared by dipping into spiked blood (Low and High QC) at 4 different Hct levels (target 
values at 0.21, 0.42, 0.52 and 0.62). The full line indicates the 0.42 Hct sample normalized to 100% and the dotted lines 
indicate the ±15 % deviation limits. 
Application 
The developed method was applied in quadruplicate on 3 sets of VAMS QCs, generated from blood in 
which external serum QC materials had been diluted 1 on 4 by replacing 250 µL of plasma with 250 
µL of the external QC. As outlined in Figure 4, 35 out of the 40 measurements deviated less than 20 % 
from the target value and the mean concentrations were within ±20 % in all cases. No trend was 
evident from the distribution of the means, compared to the target concentrations and, with the 
exception of PB from set C (owing to one deviating value), the %RSD was below 15% for the 










































Percentage of the obtained concentration in VAMS samples versus the target concentration present in 3 sets of external QC 
materials (n=4) (A: Liquicheck™ Level 2; B: ClinCal®; C: Liquicheck™ Level 3). The triangles depict the mean concentrations, 
the full line indicates the target concentration normalized to 100 % and the dotted lines represent a deviation of ±20 %. 
Next, the method was applied on 30 real-life left-over whole blood samples. Analysis was performed 
within one month after collection (storage at -20 °C). Of the collected samples, 11 contained CBZ 
(and consequently also CBZ-E), 9 VPA, 6 PB and 4 PHT. Three of the VPA samples and 1 of the CBZ 
samples had a concentration below the used LLOQ and hence were not quantified. As a reference, 
serum concentrations were obtained using chemiluminescent magnetic microparticle immunoassay 
technology (CMIA, Architect i2000SR). For VPA the mean of the VAMS concentrations were  66 ± 9.23 
% of those measured in serum, for PB 90 ±12.8 %, for PHT 83 ± 16.5 % and for CBZ 114 ± 19.7%. 
These ratios are in line with published blood/plasma ratios of 0.70 for VPA, 0.90 for PB, 0.71 for PHT 
and 1.02 for CBZ [34-36]. In theory, blood/plasma ratios could be used to calculate the serum 
concentrations, based on VAMS concentrations – with as a limitation that other techniques (i.e. 
immunoassay vs LC-MS/MS) were used for both assessments. However, as is readily clear from our 
limited dataset, there is a substantial variation in observed blood/plasma ratios between individuals. 
Also Linder et al. observed substantial variations in blood/plasma ratios for CBZ and VPA, with a role 
played by Hct and concentration, albeit using spiked samples [37]. More specifically, in our dataset, 
the %RSD on the observed blood/plasma ratios was between 14 and 20 %, yielding a significant level 
of uncertainty when applying an ‘average’ conversion coefficient. Using the published blood/plasma 
ratios to calculate serum concentration from VAMS concentrations resulted in a mean bias of -5.52, 
0.42 ,17.2, and 12.2 %, for VPA, PB, PHT and CBZ, respectively [34-36]. Given the small number of 
samples, no definitive conclusions can be drawn from this. Therefore, in conclusion, whereas this 
application on patient samples revealed applicability of the developed method on real-life patient 
samples, interpretation of the observed concentrations ideally involves the establishment of 
reference ranges in blood. 
Table 4 
%Difference between patient serum concentrations and calculated serum concentrations (calculated by dividing the VAMS 
concentration by the corresponding blood/plasma ratio) and observed blood/serum ratios for VPA, PHT, PB and CBZ. Serum 
samples were analyzed using the chemiluminescent magnetic microparticle immunoassay technology and the VAMS 







% difference between 




VPA1 29.3 41.9 49.5 -15.4 59.2
56.2 80.3 79.0 1.63 71.1
39.2 56.0 64.6 -13.3 60.7
61.7 88.1 74.7 18.0 82.6
30.0 42.9 50.6 -15.3 59.3
42.7 61.0 66.8 -8.68 63.9
Mean ± SD 
-5.52 ± 13.2 %
Mean ± %RSD
66.1 ± 14.0 %
PB2 34.9 38.8 37.8 2.59 92.3
7.35 8.17 8.70 -6.13 84.5
41.6 46.2 43.6 6.01 95.4
9.88 11.0 10.6 3.56 93.2
8.82 9.80 8.20 19.5 107.6
14.2 15.8 20.5 -23.0 69.3
Mean ± SD 
0.42 ± 14.2 %
Mean ± %RSD
90.4 ± 14.1 %
PHT3 14.3 20.1 15.8 27.5 90.5
5.47 7.70 5.32 44.8 102.8
8.31 11.7 12.4 -5.61 67.0
7.26 10.2 10.0 2.25 72.6
Mean ± SD 
17.2 ± 23.2 %
Mean ± %RSD
83.2 ± 19.8 %
CBZ4 12.2 12.0 8.60 39.1 141.9
8.56 8.39 6.50 29.1 131.7
5.91 5.79 5.20 11.4 113.7
8.75 8.58 6.40 34.0 136.7
2.71 2.66 2.30 15.5 117.8
11.7 11.5 13.1 -12.4 89.3
6.51 6.38 5.40 18.2 120.6
9.36 9.18 10.6 -13.4 88.3
6.97 6.83 7.70 -11.3 90.5
7.17 7.03 6.30 11.6 113.8
Mean ± SD 
12.2 ± 19.3 %
Mean ± %RSD












1. Blood/plasma ratio 0.7035 3. Blood/plasma ratio 0.7136




In TDM there is a growing interest in the use of non- and minimally invasive alternative sampling 
strategies, VAMS being one of the recent developments. For anti-epileptic drugs, most evidence for 
TDM exists for the first-generation anti-epileptic drugs, due to their significant interindividual 
variability in pharmacokinetics and due to the narrow therapeutic indices related to those drugs. 
In this study, an LC-MS/MS method for the determination and quantification of 4 anti-epileptic drugs 
and one active metabolite, i.e. CBZ, VPA, PHT, PB and CBZ-E, making use of VAMS devices, was 
developed and validated. The final method was extensively validated, including both bioanalytical 
and VAMS-specific parameters and overall the pre-set acceptance criteria were met. Thorough 
optimization of the extraction procedure helped enabling a Hct-independent, consistent recovery. 
Application of the method on external quality control materials and on real-life patient samples 
demonstrated the validity and applicability of the developed procedure. We successfully used 
external serum QCs to replace part of the plasma fraction of control blood, thereby yielding blood 
(and VAMS) samples with known concentrations. This represents a feasible approach to cope with 
the lack of external reference materials for dried blood matrices. 
To date, the limited availability of clinical validation data still remains one of the constraints 
preventing the widespread implementation of dried matrix approaches in clinical practice [1]. 
Furthermore, divergent results have been reported on the ratio between blood and plasma or serum 
concentrations. Therefore, calculating serum concentrations based on blood concentrations is 
challenging [9, 37-39]. Having at hand reference ranges in blood could allow to cope with this.  
As one of the advantages coupled to dried matrices is the extreme usefulness for sampling in remote 
or resource-limited settings (e.g. ease of collection and storage), in a next step, we aim at applying 
this newly developed method on patient samples originating from developing countries. 
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